Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 3/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | PRKCB | P05771 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12059151 | 0.91 | RAB9A (0.38) | BCL2A1NPC1RAB9AL3MBTL1KDM4E | |
| SCHEMBL12059075 | 0.87 | GRM2 (0.37) | GRM2KCNH2NPC1RAB9ABRD4 | |
| SCHEMBL6920638 | 0.87 | RAB9A (0.38) | GRM2KCNH2NPC1RAB9AL3MBTL1 | |
| SCHEMBL12059033 | 0.86 | RAB9A (0.37) | GRM2KCNH2NPC1RAB9ACYP1A2 | |
| SCHEMBL6922345 | 0.86 | HTR1A (0.41) | GRM2NPC1RAB9AL3MBTL1KDM4E | |
| SCHEMBL12040456 | 0.86 | GRM5 (0.38) | — | |
| SCHEMBL6921785 | 0.82 | PIM1 (0.38) | GRM2BCL2A1BRD4PIM1PIM2 | |
| SCHEMBL6921125 | 0.82 | RAB9A (0.40) | NPC1RAB9AL3MBTL1CYP1A2CYP3A4 | |
| SCHEMBL6920625 | 0.81 | APOBEC3A (0.37) | GRM2NPC1RAB9AL3MBTL1CYP1A2 | |
| SCHEMBL6920538 | 0.81 | NPC1 (0.41) | NPC1RAB9AL3MBTL1KDM4EPRKCB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011075699-A2 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2011-06-23 | — | — | WO | disclosed |